Tag: HTBX

In a report issued on February 2, Jason McCarthy from Maxim Group maintained a Buy rating on Heat Biologics (HTBX – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $2.76, close to its 52-week low of $2.45.

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

Heat Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing a 449.5% upside. In a report issued on January 21, B.Riley Financial also maintained a Buy rating on the stock with a $10.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Heat Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $501.6K and GAAP net loss of $7.43 million. In comparison, last year the company earned revenue of $849.7K and had a GAAP net loss of $8.85 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient’s T-cell mediated immune system against cancer. The company’s T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company’s ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

Read More on HTBX:

• Wells Fargo Keeps Their Buy Rating on Ryman (RHP)
• Needham Remains a Hold on Qualys (QLYS)
• Maxim Group Maintains Their Buy Rating on Mesoblast (MESO)
• Wells Fargo Remains a Hold on RLJ Lodging (RLJ)
• Host Hotels & Resorts (HST) Receives a Hold from Wells Fargo

In a report issued on January 21, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Heat Biologics (HTBX – Research Report), with a price target of $10.00. The company’s shares closed last Friday at $2.71, close to its 52-week low of $2.67.

According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.4% and a 29.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Heat Biologics with a $15.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Heat Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $501.6K and GAAP net loss of $7.43 million. In comparison, last year the company earned revenue of $849.7K and had a GAAP net loss of $8.85 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient’s T-cell mediated immune system against cancer. The company’s T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company’s ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

Read More on HTBX:

• Berenberg Bank Believes Mondelez International (MDLZ) Still Has Room to Grow
• Northern (NTRS) Gets a Buy Rating from Jefferies
• Rosenblatt Securities Reaffirms Their Hold Rating on Western Digital (WDC)
• Rosenblatt Securities Maintains a Buy Rating on Texas Instruments (TXN)
• Wells Fargo Thinks Stanley Black & Decker’s Stock is Going to Recover

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Heat Biologics (HTBX – Research Report), with a price target of $15.00. The company’s shares closed last Tuesday at $3.93, close to its 52-week low of $3.76.

According to TipRanks.com, Mamtani is a 2-star analyst with an average return of 1.0% and a 40.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.

Heat Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.

See today’s best-performing stocks on TipRanks >>

Based on Heat Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $501.6K and GAAP net loss of $7.43 million. In comparison, last year the company earned revenue of $849.7K and had a GAAP net loss of $8.85 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient’s T-cell mediated immune system against cancer. The company’s T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company’s ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

Read More on HTBX:

• MHRA Authorizes Deciphera’s QINLOCK in the U.K.
• Synopsys Updates 2 Key Risk Factors
• Microsoft Wins EU Antitrust Approval for $16B Nuance Deal
• Wednesday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
• Wedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)